期刊文献+

原发性胆汁性肝硬化药物治疗进展 被引量:9

Advances in pharmacotherapy of patients with primary biliary cirrhosis
下载PDF
导出
摘要 治疗原发性胆汁性肝硬化(PBC)的药物主要包括加速胆汁排泄、免疫调节、抗纤维化以及对症治疗等。熊去氧胆酸是目前唯一被批准治疗PBC的药物,对大多数患者有较好的疗效,但仍有部分患者不应答。另外,贝特类、6-乙基鹅去氧胆酸、布地奈德等用于PBC的治疗也显示有很好的前景,这些研究结果为PBC的治疗提供了新选择。 Primary biliary cirrhosis (PBC) is one of the autoimmune liver diseases. Ursedeoxycholie acid (UDCA) is the only therapeutic drug approved by FDA. Most patients have a good response to UDCA. Many research on treatment of PBC for the use of fibrates,6- ethyl ehenedeoxycholic acid,and budesonide, shows promising results.
出处 《实用肝脏病杂志》 CAS 2015年第4期441-444,共4页 Journal of Practical Hepatology
关键词 原发性胆汁性肝硬化 药物治疗 进展 Primary biliary cirrhosis Ursodeoxycholic acid Budesonide
  • 相关文献

参考文献34

  • 1Selmi C,Bowlus CL,Gershwin ME,et al. Primary biliary cir- rhosis. Lancet, 2011,377 : 1600-1609.
  • 2Boberg KM,Wisloff T,Kjollesdal KS,et al. Cost and health conse- quences of treatment of primary biliary cirrhosis with ursodeoxy- cholic acid. Aliment Pharmacol Ther,2013,38(7):794-803.
  • 3Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatie liver diseases:an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol, 2012,36(Suppl 1 ) : S3-S 12.
  • 4Leuschner U,Manns MP,Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis:effects on progression and prognosis. Z Gastroenterol,2005,43(9):1051-1059.
  • 5Rautiainen H,Karkkainen P,Karvonen AL,et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial. Hepatology, 2005,41 ( 4 ) : 747-752.
  • 6Corpechot C,Abenavoli L,Rabahi N,et al. Biochemical re- sponse to ursodeoXycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology, 2008,48 : 871-877.
  • 7Fiorucci S,Cipriani S,Mencarelli A,et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: fo- cus on 6-ethyl-CDCA. Mini Rev Med Chem,2011,11(9): 753-762.
  • 8Beuers U,Boberg KM,Chapman RW,et al. EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51 (2) : 237-267.
  • 9Cash W J, O'Neill S,O'Donnell ME,et al. Randomized con- trolled trial assessing the effect of simvastatin in primary bil- iary cirrhosis. Liver Int, 2013,33(8 ) : 1166-1174.
  • 10Stojakovic T,Putz-Bankuti C,Fauler G,et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochem- ical response to ursodeoxycholic acid. Hepatology, 2007,46(3): 776-784.

同被引文献96

引证文献9

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部